Infarma Madrid 2022: Medical cannabis for discussion

 

 

 


/COMUNICAE/

According to Infarma, a major debate has been held at its fair on the use of medicinal cannabis and its teacher formulas where the need for prompt regulation has been discussed

Infarma a large debate with experts held in the framework of Infarma Madrid 2022, the European Congress of Pharmacy Office and Parapharmacy Hall on April 5, 2022 on the use of cannabis in the treatment of diseases in the Fairground IFEMA Madrid.

In particular, under the title “Therapeutic use of Cannabis. Social Reivindication vs. health impact“ Several experts addressed the clinical application of cannabis, a plant “full of opportunities and potential”.

 

At the meeting, according to reports Europe Press, Guillermo Bagaria de Casanova, member of the Pharmacy Office and responsible for professional projects of the Barcelona School of Pharmaceuticals and moderator of the debate, said that there is “a clear map of what is and what should not be considered medicine and what properties can be attributed to each product.”

“We are from the counter of the pharmacy what kind of response we are giving to a need that moves society regarding the suitability of a treatment or combination with treatments. And we do it from the rigor, knowledge and commitment to patient health because there is an important and dual risk. On the one hand, banalization, that is, we do not give it the context that requires as a health resource and loses credibility over time, and, on the other, the stigmatization that prevents us from seeing beyond that rejection of a drug. It has an important potential as a sanitary use that needs to be contextualized,” said Bagaria de Casanova.

Josep Allué Creus, expert in Medical Plants and Homeopathy of the COFB, also highlighted the two drugs currently authorized in Spain for multiple sclerosis, and as complementary treatment for seizures associated with Dravet syndrome.

He also highlighted other health conditions and problems in which there is scientific evidence of their benefits, such as chronic pain, ulcerative colitis, Crohn's disease and epilepsy. “The cannabis plant is safe in proper use with medical control. There are many studies that prove it,” said Josel Allué Creus. Blog sobre productos para la limpieza del hogar

Thus, the debate has asked for the reasons why it is questioned that it works if there are two drugs on the market. Manel Rabanal Tornero, head of Pharmaceutical Quality and Ordering Service of the Generalitat de Catalunya, argued that “limiting the debate whether it works or not is a stage that we have already overcome and we have to move to the next.”

The pharmacist in Spain “has the technical capacity to become a fundamental pillar through a tool such as the magistral formulation (FM). We should start having control of these products through the FM. There are many substances on this plant that we can use therapeutically and the FM allows us to approach this therapeutic strategy. And here the pharmacist is key. The FM is the way to individualize treatment to patients. We must give him the consideration he deserves” explained Mery Peña Guzmán, doctor and secretary of the Clinical Society of Endocannabinology.

In the same line, Manel Rabanal defended that, along with authorised and special-use medications, the master formulation would be “the third step as individualized treatment.” Thousands of users purchase cannabis products daily in large online markets such as Hannapy, where more than a thousand products can be found, although by the regulatory characteristics of the market, they can only be sold as cosmetic or aromatic products.

However, he clarified that it is necessary to protocolize the quality standards of the product. “It would be necessary to have a consensus document in which the categories are respected (medication, special use medicine and FM) by guaranteeing quality standards. Because these three options would make us flee from the part of cosmetic products and food supplements, which are swamp soils,” he said.

Although there is no regulatory framework in Spain, “the reality is that more and more people come to this substance looking for a therapeutic effect, and the desire as doctors is to accompany these patients in a responsible way who are under a state of significant vulnerability. They have suffered a lot and have exhausted the therapeutic and pharmaceutical options we have with. They come with difficult expectations to handle, because cannabis is a chemically complex and special plant, and patients must have real information that often does not have for the marketing that exists and is growing,” said Dr. Peña.

Infarma Madrid 2022: Medical cannabis for discussion

Infarma Madrid 2022: Medical cannabis for discussion

According to Infarma, a major debate has been held at its fair on the use of medicinal cannabis and its teacher formulas where the need for prompt regulation h

nails

en

https://nails-trends.com/static/images/nails-infarma-madrid-2022-medical-cannabis-for-discussion-807-0.jpg

2023-04-11

 

Infarma Madrid 2022: Medical cannabis for discussion
Infarma Madrid 2022: Medical cannabis for discussion

Acording with the Digital Millennium Copyright Act (“DMCA”), Pub. L. 105-304 If you believe that your copyrighted work is being infringed, notify our team at the email bitelchux@yahoo.es

 

 

Top 20